<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-section" /><meta name="keywords" content="Normal immunoglobulin see Immunoglobulins, normal; HNIG see Immunoglobulins, normal; Immunoglobulins: normal; Immunodeficiency; Congenital agammaglobulinaemia, replacement therapy; Agammaglobulinaemia, congenital, replacement therapy; Hypogammaglobulinaemia; Thrombocytopenic purpura: immunoglobulin; Kawasaki syndrome; Guillain-Barré syndrome; Hepatitis A: immunoglobulin, normal; Measles: immunoglobulin, normal; Rubella: immunoglobulin, normal" /><meta name="IX" content="Immunoglobulins: normal; Immunodeficiency; Congenital agammaglobulinaemia, replacement therapy; Agammaglobulinaemia, congenital, replacement therapy; Hypogammaglobulinaemia; Thrombocytopenic purpura: immunoglobulin; Kawasaki syndrome; Guillain-Barré syndrome; Hepatitis A: immunoglobulin, normal; Measles: immunoglobulin, normal; Rubella: immunoglobulin, normal" /><meta name="IXN" content="Normal immunoglobulin see Immunoglobulins, normal; HNIG see Immunoglobulins, normal" /><title>14.5.1 Normal immunoglobulin: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="202710.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="202710.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=202710.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2081.htm">14 Immunological products and vaccines</a> &gt; <a href="6538.htm">14.5 Immunoglobulins</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="6538.htm" title="Previous: 14.5 Immunoglobulins">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="202693.htm" title="Next: NORMAL IMMUNOGLOBULIN">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_202710">14.5.1 Normal immunoglobulin</h1><?highlighter on?><div id="pC" class="jN"><div><p>Human <b>normal
immunoglobulin </b>(‘HNIG’) is prepared from pools of at least
1000 donations of human plasma; it contains immunoglobulin G (IgG)
and antibodies to hepatitis A, measles, mumps, rubella, varicella,
and other viruses that are currently prevalent in the general population.</p><div id="_202708"><p>Normal immunoglobulin may <b>interfere with the
immune response to live virus vaccines</b> which should therefore
only be given <b>at least 3 weeks before or 3 months after</b> an injection of normal immunoglobulin (this does not apply to yellow
fever vaccine since normal immunoglobulin does not contain antibody
to this virus).</p></div><div class="cAZ"><h2>Uses</h2> <p class="cAX">Normal immunoglobulin (containing 10%–18%)
is administered by <i>intramuscular injection</i> for the
protection of susceptible contacts against <b>hepatitis A</b> virus (infectious hepatitis), <b>measles</b> and, to a
lesser extent, <b>rubella</b>. Injection of immunoglobulin
produces immediate protection lasting several weeks. </p><p>Normal immunoglobulin (containing 3%–12% protein) for <i>intravenous administration</i> is used as <i>replacement
therapy</i> for patients with congenital agammaglobulinaemia and hypogammaglobulinaemia,
and for the short-term treatment of idiopathic thrombocytopenic
purpura and Kawasaki
syndrome; it is also used for the prophylaxis of infection following
bone-marrow transplantation and in children with symptomatic HIV infection
who have recurrent bacterial infections. Normal immunoglobulin for
replacement therapy may also be given intramuscularly or subcutaneously,
but intravenous formulations are normally preferred. Intravenous immunoglobulin
is also used in the treatment of Guillain-Barré syndrome as an alternative
to plasma exchange.</p><p>For guidance on the use of intravenous normal immunoglobulins
and alternative therapies for certain conditions, consult <i>Clinical Guidelines for Immunoglobulin Use</i> (<a href="http://www.dh.gov.uk" title="external link">www.dh.gov.uk</a>).</p></div><div id="_202709"><div class="cAZ"><h2>Hepatitis A</h2> <p class="cAX"><b>Hepatitis A vaccine</b> is preferred for individuals at risk of infection (see <a title="monograph-family: Hepatitis A vaccine" href="6486.htm#_6486">Hepatitis A vaccine</a>) including
those visiting areas where the disease is highly endemic (all countries
excluding Northern and Western Europe, North America, Japan, Australia,
and New Zealand). In unimmunised individuals, transmission of hepatitis
A is reduced by good hygiene. Intramuscular normal immunoglobulin
is no longer recommended for routine prophylaxis in travellers, but
it may be indicated for immunocompromised patients if their antibody
response to the vaccine is unlikely to be adequate.</p><p>Intramuscular normal immunoglobulin is recommended for prevention
of infection in close contacts (of confirmed cases of hepatitis A)
who have chronic liver disease or HIV infection, or who are immunosuppressed
or over 50 years of age; normal immunoglobulin should be given as
soon as possible, preferably within 14 days of exposure to the primary
case. However, normal immunoglobulin can still be given to contacts
at risk of severe disease up to 28 days after exposure to the primary
case. Hepatitis A vaccine can be given at the same time, but it should
be given at a separate injection site.</p></div></div><div id="_6539.2"><div class="cAZ"><h2>Measles</h2> <p class="cAX">Intravenous or subcutaneous normal immunoglobulin
may be given to prevent or attenuate an attack of measles in individuals
who do not have adequate immunity. Children and adults with compromised
immunity who have come into contact with measles should receive intravenous
or subcutaneous normal immunoglobulin as soon as possible after exposure.
It is most effective if given within 72 hours but can be effective
if given within 6 days.</p><p>Subcutaneous or intramuscular normal immunoglobulin should also
be considered for the following individuals if they have been in contact
with a confirmed case of measles or with a person associated with
a local outbreak:</p><ul class="cBF"><li><p class="cQ">non-immune pregnant women;</p></li><li><p class="cQ">infants under 9 months.</p></li></ul><p>Further advice should be sought from the Centre for Infections,
Health Protection Agency (tel. (020) 8200 6868).</p><p>Individuals with normal immunity who are not in the above categories
and who have not been fully immunised against measles, can be given
MMR vaccine (<a title="monograph-family: MMR vaccine" href="6498.htm#_6498">section 14.4</a>) for prophylaxis following exposure
to measles.</p></div></div><div id="_202825"><div class="cAZ"><h2>Rubella</h2> <p class="cAX">Intramuscular immunoglobulin after exposure to
rubella does <b>not</b> prevent infection in non-immune
contacts and is <b>not</b> recommended for protection of
pregnant women exposed to rubella. It may, however, reduce the likelihood
of a clinical attack which may possibly reduce the risk to the fetus.
Risk of intrauterine transmission is greatest in the first 11 weeks
of pregnancy, between 16 and 20 weeks there is minimal risk of deafness
only, after 20 weeks there is no increased risk. Intramuscular normal
immunoglobulin should be used only if termination of pregnancy would
be unacceptable to the pregnant woman—it should be given as soon as
possible after exposure. Serological follow-up of recipients is essential
to determine if the woman has become infected despite receiving immunoglobulin.</p><p>For routine prophylaxis against Rubella, see <a title="monograph-family: Measles, Mumps and Rubella (MMR) vaccine" href="6498.htm#_6498">MMR vaccine</a>.</p></div></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_202693"><a href="202693.htm" title="NORMAL IMMUNOGLOBULIN">NORMAL IMMUNOGLOBULIN</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="6538.htm">Previous: 14.5 Immunoglobulins</a> | <a class="top" href="202710.htm#">Top</a> | <a accesskey="]" href="202693.htm">Next: NORMAL IMMUNOGLOBULIN</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>